Skip to main content

Table 1 Clinicopathological characteristics of patient samples and expression of FLOT2 in breast cancer patients

From: Flotillin-2 is associated with breast cancer progression and poor survival outcomes

  Number of cases (%)
Sex  
Male 0(0.0)
Female 171(100.0)
Age (years)
≥47 85(49.7)
<47 86(50.3)
Clinical stage
I 21(12.3)
II 92(53.8)
III 46(26.9)
IV 12(7.0)
T classification
T1 35(20.5)
T2 89(52.0)
T3 35(20.5)
T4 12(7.0)
N classification
N0 70(40.9)
N1 65(38.0)
N2 27(15.8)
N3 9(5.3)
M classification
No 159(93.0)
Yes 12(7.0)
Vital status (at follow-up)
alive 113(66.1)
Dead 58(33.9)
Histological differentiation
Well 9(5.3)
Moderate 113(66.1)
Poor 49(28.7)
Expression of FLOT2
Low expression 89(52.0)
High expression 82(48.0)
Expression of ER
0 77(45.0)
1 82(48.0)
2 8(4.73)
3 4(2.3)
Expression of PR
0 71(41.5)
1 80(46.8)
2 16(9.4)
3 3(1.8)
4 1(0.6)
Expression of ErbB-2
0 42(24.6)
1 52(30.4)
2 38(22.2)
3 30(17.5)